Share on StockTwits

Achillion Pharmaceuticals (NASDAQ:ACHN) announced its earnings results on Thursday. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.02, American Banking News reports.

Achillion Pharmaceuticals (NASDAQ:ACHN) traded down 0.85% on Thursday, hitting $7.00. The stock had a trading volume of 1,691,717 shares. Achillion Pharmaceuticals has a 1-year low of $2.26 and a 1-year high of $8.61. The stock’s 50-day moving average is $7.26 and its 200-day moving average is $4.41. The company’s market cap is $677.6 million.

A number of analysts have recently weighed in on ACHN shares. Analysts at Wells Fargo & Co. raised their price target on shares of Achillion Pharmaceuticals to $8.00 in a research note on Monday, June 23rd. On the ratings front, analysts at Maxim Group raised their price target on shares of Achillion Pharmaceuticals from $6.00 to $22.00 in a research note on Monday, June 16th. They now have a “buy” rating on the stock. Finally, analysts at Robert W. Baird upgraded shares of Achillion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Wednesday, June 11th. They now have a $12.00 price target on the stock, up previously from $4.00. One research analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the stock. Achillion Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $8.10.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.